TARK Biopharma Co., Ltd.
Established in 2020, TARK Biopharma is an innovative biotechnology company committed to advancing small-molecule new molecular entities (NMEs).
Guided by our mission to address unmet clinical needs, we focus on developing transformative therapies that deliver breakthrough solutions for major diseases.
With a foundation of scientific excellence and innovation, we aspire to improve patient outcomes and make a lasting impact on global healthcare.
Guided by our mission to address unmet clinical needs, we focus on developing transformative therapies that deliver breakthrough solutions for major diseases.
With a foundation of scientific excellence and innovation, we aspire to improve patient outcomes and make a lasting impact on global healthcare.
Innovative Medicine,
Benefiting the Future
Benefiting the Future
By integrating cutting-edge AI technologies with deep scientific expertise, we accelerate the drug development process from preclinical research to clinical stages. At every step, we are committed to creating safer and more effective therapeutic options that improve the health and quality of life of patients worldwide.
TARK Biopharma represents not only the fusion of science and innovation but also the commitment to care and responsibility for life. We continue to work hand in hand with the medical community to shape a healthier and brighter future for patients across the globe.
TARK Biopharma represents not only the fusion of science and innovation but also the commitment to care and responsibility for life. We continue to work hand in hand with the medical community to shape a healthier and brighter future for patients across the globe.
Product Development Model
TARK Biopharma Co., Ltd. is committed to advancing new drug candidates into clinical trials.
All pipeline products undergo comprehensive preclinical testing before submitting IND applications to the FDA and TFDA.
Upon entering clinical trials, we aim to complete Phase 1 or Phase 2a studies and then seek licensing opportunities with pharmaceutical partners, creating new possibilities in drug development and patient care.
All pipeline products undergo comprehensive preclinical testing before submitting IND applications to the FDA and TFDA.
Upon entering clinical trials, we aim to complete Phase 1 or Phase 2a studies and then seek licensing opportunities with pharmaceutical partners, creating new possibilities in drug development and patient care.
